Delving into the Latest Updates on Yiling Pharmaceutical Ltd. with Synapse

Overview

Tags

Congenital Disorders

Nervous System Diseases

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

COX(Cyclooxygenases)	1

以美国礼来公司持证的他达拉非片（规格：20mg）为参比制剂，以以岭万洲国际制药有限公司生产的他达拉非片（规格：20mg）为受试制剂，通过随机、开放、两周期、自身交叉的临床试验进行人体生物利用度与生物等效性试验，并观察两制剂在健康受试者中的安全性。

[Translation]

Using the tadalafil tablets (specification: 20 mg) certified by Eli Lilly and Company of the United States as the reference preparation, and the tadalafil tablets (specification: 20 mg) produced by Yiling Wanzhou International Pharmaceutical Co., Ltd. as the test preparation, human bioavailability and bioequivalence tests were conducted through a randomized, open, two-period, self-crossover clinical trial, and the safety of the two preparations in healthy subjects was observed.

Start Date19 Feb 2024

Sponsor / Collaborator

Yiling Pharmaceutical Ltd.

CTR20231663 / CompletedPhase 1

单中心、随机、开放、两制剂、两周期、双交叉设计评价空腹条件下健康受试者单次口服布洛芬多释片(800mg，QD给药)、早晚服用布洛芬缓释胶囊(芬必得®)(400mg，BID给药)的比较药代动力学临床研究

[Translation] A single-center, randomized, open-label, two-dose, two-period, double-crossover design was used to evaluate the pharmacokinetics of a single oral dose of ibuprofen extended-release tablets (800 mg, QD administration) and morning and evening administration of ibuprofen sustained-release capsules (Fenbid®) (400 mg, BID administration) in healthy subjects under fasting conditions.

主要目的：以布洛芬缓释胶囊(400mg，芬必得®，中美天津史克制药有限公司)为参比制剂，以布洛芬多释片(800mg，越洋医药开发(广州)有限公司)为受试制剂，通过单中心、随机、开放、两周期、双交叉的临床试验设计，为正式试验采血点设计的合理性提供依据，同时估算个体内变异系数，以调整正式试验的样本量。次要目的：？初步观察并比较IBUMR和芬必得的PK曲线；？通过检测血浆中布洛芬的浓度初步观察给药后IBUMR的作用持续时间；？初步评估IBUMR给药后的安全性。

[Translation]

Main purpose: Using ibuprofen sustained-release capsules (400 mg, Fenbid®, Sino-US Tianjin SmithKline Pharmaceutical Co., Ltd.) as the reference preparation and ibuprofen extended-release tablets (800 mg, Yueyang Pharmaceutical Development (Guangzhou) Co., Ltd.) as the test preparation, a single-center, randomized, open, two-period, double-crossover clinical trial design was conducted to provide a basis for the rationality of the design of blood sampling points for the formal trial, and to estimate the intra-individual coefficient of variation to adjust the sample size of the formal trial. Secondary purpose: ? Preliminary observation and comparison of the PK curves of IBUMR and Fenbid; ? Preliminary observation of the duration of action of IBUMR after administration by detecting the concentration of ibuprofen in plasma; ? Preliminary evaluation of the safety of IBUMR after administration.

Start Date14 Nov 2023

Sponsor / Collaborator

Overseas Pharmaceuticals Ltd.

[+1]

100 Clinical Results associated with Yiling Pharmaceutical Ltd.

Login to view more data

0 Patents (Medical) associated with Yiling Pharmaceutical Ltd.

Login to view more data

1

Literatures (Medical) associated with Yiling Pharmaceutical Ltd.

Medical Sciences

Dually Efficacious Medicine Against Fibrosis and Cancer

Review

Author: Chen, Daohong

Although there is a contemporary consensus of managing a severe disease with multi-targeted approach-based therapeutic combinations, it should not be ignored that certain patho-biological pathways are shared by distinct medical conditions and can be exploited to develop an exceptional type of medication conferring a dual efficacy. This article thus presents a spectrum of emerging molecular targets that substantially contribute to the pathogenesis of both fibrotic and neoplastic disorders, including kinase activities, cytokine cascades, and protein dynamics among others. Moreover, recently approved therapeutic agents in this regard have been sorted out to corroborate the drug’s ability upon targeting each one of these molecular pathways to treat fibrosis and cancer simultaneously. It not only streamlines an overlapping mechanistic profile in the pathogenesis across these two medical conditions, but also inspires clinicians and pharmaceutical innovation to tackle concomitant diseases, such as fibrosis and cancer, with an optimally efficacious medication.

1

News (Medical) associated with Yiling Pharmaceutical Ltd.

13 Oct 2023

·www.prnewswire.com

Yiling Pharmaceutical's Shensong Yangxin Capsules Have Obtained Registration in Nigeria--Study Has Shown that It Significantly Improves the Prognosis of Patients After Radiofrequency Ablation

SHIJIAZHUANG, China, Oct. 13, 2023 /PRNewswire/ -- Recently, the National Agency for Food and Drug Administration and Control (NAFDAC) of Nigeria disclosed that the innovative patented traditional Chinese medicine (TCM), Shensong Yangxin Capsules, developed and produced by Yiling Pharmaceutical, has been granted registration in Nigeria under the category of "Herbal and Natural Medicines". Shensong Yangxin Capsules can significantly alleviate clinical symptoms such as palpitations, shortness of breath, fatigue, insomnia, and dreaminess. In August of this year, at the European Society of Cardiology Congress, a top-tier international academic conference in the field of cardiovascular medicine, the latest study results from Prof. He Huang's team at Wuhan University People's Hospital in China were disclosed. The results showed that the addition of Shensong Yangxin Capsules to standard of care could reduce the risk of atrial fibrillation recurrence within one year by about 40%, significantly improve patients' health-related Quality of life (QoL) scores and demonstrate excellent safety. This study provides a brand new treatment strategy for the prognosis of atrial fibrillation patients after radiofrequency ablation. A number of evidence-based medical studies have confirmed that Shensong Yangxin Capsules can effectively treat fast arrhythmia such as premature beats and paroxysmal atrial fibrillation; increase the slow heart rate to treat slow arrhythmia; and effectively treat complex arrhythmia such as heart failure with premature beats and sinus bradycardia with premature ventricular beats, filling the gap of drugs for both tachyarrhythmia and bradycardia at home and abroad. The "Construction of Traditional Chinese Medicine Collateral Theory and Its Guidance on Preventing and Treating Microvascular Lesions" project, which includes important studies related to Shensong Yangxin Capsules, was awarded the sole First Prize for National Science and Technology Progress in the field of life sciences in 2019. As of now, Yiling Pharmaceutical has received approval for six innovative patented traditional Chinese medicines to enter Nigeria, including Lianhua Qingwen Capsules, Tongxinluo Capsules, Qili Qiangxin Capsules, Bazi Bushen Capsules, Lianhua Qingke Tablets, and Shensong Yangxin Capsules. SOURCE Yiling Pharma

Drug Approval

100 Deals associated with Yiling Pharmaceutical Ltd.

Login to view more data

100 Translational Medicine associated with Yiling Pharmaceutical Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Other

Login to view more data